Abstract

Admittedly, the disastrous emergence of drug resistance in prokaryotic and eukaryotic human pathogens has created an urgent need to develop novel chemotherapeutic agents. Onosma chitralicum is a source of traditional medicine with cooling, laxative, and anthelmintic effects. The objective of the current research was to analyze the biological potential of Onosma chitralicum, and to isolate and characterize the chemical constituents of the plant. The crude extracts of the plant prepared with different solvents, such as aqueous, hexane, chloroform, ethyl acetate, and butanol, were subjected to antimicrobial activities. Results corroborate that crude (methanol), EtoAc, and n-C6H14 fractions were more active against bacterial strains. Among these fractions, the EtoAc fraction was found more potent. The EtoAc fraction was the most active against the selected microbes, which was subjected to successive column chromatography, and the resultant compounds 1 to 7 were isolated. Different techniques, such as UV, IR, and NMR, were used to characterize the structures of the isolated compounds 1–7. All the isolated pure compounds (1–7) were tested for their antimicrobial potential. Compounds 1 (4′,8-dimethoxy-7-hydroxyisoflavone), 6 (5,3′,3-trihydroxy-7,4′-dimethoxyflavanone), and 7 (5′,7,8-trihydroxy-6,3′,4′-trimethoxyflavanone) were found to be more active against Staphylococcus aureus and Salmonella Typhi. Compound 1 inhibited S. typhi and S. aureus to 10 ± 0.21 mm and 10 ± 0.45 mm, whereas compound 6 showed inhibition to 10 ± 0.77 mm and 9 ± 0.20 mm, respectively. Compound 7 inhibited S. aureus to 6 ± 0.36 mm. Compounds 6 and 7 showed significant antibacterial potential, and the structure–activity relationship also justifies their binding to the bacterial enzymes, i.e., beta-hydroxyacyl dehydratase (HadAB complex) and tyrosyl-tRNA synthetase. Both bacterial enzymes are potential drug targets. Further, the isolated compounds were found to be active against the tested fungal strains. Whereas docking identified compound 7, the best binder to the lanosterol 14α-demethylase (an essential fungal cell membrane synthesizing enzyme), reported as an antifungal fluconazole binding enzyme. Based on our isolation-linked preliminary structure-activity relationship (SAR) data, we conclude that O. chitralicum can be a good source of natural compounds for drug development against some potential enzyme targets.

Highlights

  • Microorganisms, including viruses, bacteria, and others, are potentially harmful to other living organisms, mainly humans

  • We report the antibacterial and antifungal activities of the crude extract, solvents soluble fractions, and new source compounds (1–7) isolated for the first time from Onosma chitralicum, but reported already from different sources as referenced in the Materials and Methods section, which were individualized by various techniques named one-dimensional (1D) and two-dimensional (2D) NMR

  • The fraction was active against fungal strains A. flavus and F. solani with inhibition zones of 60 ± 0.94 mm and 57 ± 0.51 mm, respectively

Read more

Summary

Introduction

Microorganisms, including viruses, bacteria, and others, are potentially harmful to other living organisms, mainly humans. Bacteria largely become resistant to antibiotics, throughout the world, as examined in many hospital studies [1] For this reason, the discovery of new and modified broad-spectrum antibiotics is very important and essential to overcome diseases. Many bacterial strains acquired resistance against various antibiotics due to changes in their structures, mutations in their genes, and most importantly, due to excessive unselective intake of antibiotics for the treatment of various infectious diseases. All of these modifications result in the usefulness of most antibiotics and generate a renewed interest in herbal medicines [4]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call